A Phase 4 interventional study of Glimepiride/metformin and Metformin in Endothelial Dysfunction and Diabetes Mellitus, sponsored by Laboratorios Silanes S.A. de C.V.. Completed at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-09-07.
Sponsored by Laboratorios Silanes S.A. de C.V. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing glimepiride in Diabetes Mellitus — 1 open to participants now, 1 under way, none of them phase 3. glimepiride · Diabetes Mellitus.
Among the 14 studies testing glimepiride in Diabetes Mellitus, this one is the 14th largest by enrollment, is the only one that started in 2007, is one of 5 in phase 4, and was the 10th registered.
8,294 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →1 of the 14 studies testing glimepiride in Diabetes Mellitus is open now, in 1 country. Recruiting first, the newest first:
Washington University School of Medicine · Sites in Nigeria
Ages 18+
By country, each count listing its studies:
glimepiride: first FDA approval 1995 (AMARYL), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 649 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 7 · Phase 4 5
First in 2002; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 80 across 6,026 interventional studies indexed under Diabetes Mellitus.
Median enrollment 286 across the 14 interventional studies. Of the 13 that completed or were terminated, 4 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 9 most frequent:
Laboratorios Silanes S.A. de C.V. is the lead sponsor of 45 studies on the registry; 1 is open to participants now.
Laboratorios Silanes S.A. de C.V. has 5 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing glimepiride in Diabetes Mellitus, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Purpose of this study was to evaluate the effect of the combination glimepiride/metformin over endothelial dysfunction (ED) in asymptomatic patients with type 2 diabetes mellitus (DM) using 13N-ammonia-positron emission tomography (PET).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Glimepiride/metformin
Drug: Metformin
Drug pages: Glimepiride · Metformin
4/1000 mg tablets once a day foe eight weeks
Also known as: GLIMETAL
1000 mg tablets once daily for eight weeks
Also known as: PREDIAL
EDVI
endothelial-dependent vasodilation index
Time frame: 8 weeks
MFR
myocardial flow reserve
Time frame: 8 weeks
%ΔMBF
percentage of the change between rest and CPT
Time frame: 8 weeks
Fasting glucose
Time frame: 8 weeks
Glycated hemoglobin
Time frame: 8 weeks
Adverse effects
Time frame: 8 weeks
The record gives a start of Jul 2007, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Glimepiride · Metformin
Laboratorios Silanes S.A. de C.V. →